Lupin launches cardiovascular drug in US market

According to the company, the Rivaroxaban Tablets USP, 2.5 mg tablets are a bioequivalent of Janssen Pharmaceuticals’ Xarelto® Tablets, 2.5 mg, which generated an estimated $446 million in sales annually in the US.

Shares of Lupin closed at ₹2,029.00, up 0.52% on the National Stock Exchange (NSE). However, it announced the new drug launch after market hours.

The newly launched drug will be used to reduce the risk of major cardiovascular events in patients with coronary artery disease (CAD). Additionally, it will help “to reduce the risk of major thrombotic vascular events in patients with peripheral artery disease (PAD), including patients after recent lower extremity revascularisation due to symptomatic PAD,” the company said in a regulatory filing.

Lupin share performance

Lupin shares gained 6.58% over the week but have lost 8.45% since the beginning of February. The scrip has fallen 13.83% on a year-to-date basis.

It hit its 52-week high of ₹2,402.90 on January 2, 2025 and low of ₹1,493.30 on June 4, 2024

The pharmaceutical company has a total market cap of ₹92,632.16 crore as of March 7, 2025, on the NSE.

About Lupin

Headquartered in Mumbai, Lupin is a global pharmaceutical company with operations spread across 100 markets. It specialises in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products and active pharmaceutical ingredients.